PubMed:33113325
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1050-1057 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T2 | 1050-1057 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T3 | 1864-1871 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T4 | 1864-1871 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-167 | Sentence | denotes | Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series. |
T2 | 168-181 | Sentence | denotes | INTRODUCTION: |
T3 | 182-377 | Sentence | denotes | Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS). |
T4 | 378-585 | Sentence | denotes | We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support. |
T5 | 586-594 | Sentence | denotes | METHODS: |
T6 | 595-695 | Sentence | denotes | Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored. |
T7 | 696-919 | Sentence | denotes | Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen. |
T8 | 920-1109 | Sentence | denotes | Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds. |
T9 | 1110-1118 | Sentence | denotes | RESULTS: |
T10 | 1119-1301 | Sentence | denotes | Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging). |
T11 | 1302-1450 | Sentence | denotes | The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days. |
T12 | 1451-1629 | Sentence | denotes | Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen. |
T13 | 1630-1641 | Sentence | denotes | CONCLUSION: |
T14 | 1642-1835 | Sentence | denotes | Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure. |
T15 | 1836-2054 | Sentence | denotes | The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery. |
T1 | 0-167 | Sentence | denotes | Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series. |
T2 | 168-181 | Sentence | denotes | INTRODUCTION: |
T3 | 182-377 | Sentence | denotes | Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS). |
T4 | 378-585 | Sentence | denotes | We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support. |
T5 | 586-594 | Sentence | denotes | METHODS: |
T6 | 595-695 | Sentence | denotes | Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored. |
T7 | 696-919 | Sentence | denotes | Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen. |
T8 | 920-1109 | Sentence | denotes | Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds. |
T9 | 1110-1118 | Sentence | denotes | RESULTS: |
T10 | 1119-1301 | Sentence | denotes | Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging). |
T11 | 1302-1450 | Sentence | denotes | The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days. |
T12 | 1451-1629 | Sentence | denotes | Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen. |
T13 | 1630-1641 | Sentence | denotes | CONCLUSION: |
T14 | 1642-1835 | Sentence | denotes | Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure. |
T15 | 1836-2054 | Sentence | denotes | The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery. |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 35-40 | Body_part | denotes | Blood | http://purl.org/sig/ont/fma/fma9670 |
T2 | 504-509 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T3 | 759-770 | Body_part | denotes | interleukin | http://purl.org/sig/ont/fma/fma86578 |
T4 | 772-774 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T5 | 779-781 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T6 | 827-834 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T7 | 856-866 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
T8 | 874-885 | Body_part | denotes | thrombocyte | http://purl.org/sig/ont/fma/fma62851 |
T9 | 979-984 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T10 | 1050-1057 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T11 | 1266-1270 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T12 | 1520-1532 | Body_part | denotes | thrombocytes | http://purl.org/sig/ont/fma/fma62851 |
T13 | 1537-1554 | Body_part | denotes | white blood cells | http://purl.org/sig/ont/fma/fma62852 |
T14 | 1549-1554 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T15 | 1573-1575 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
T16 | 1864-1871 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T17 | 1916-1921 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T18 | 1941-1949 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 35-40 | Body_part | denotes | Blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T2 | 504-509 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T3 | 979-984 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T4 | 1266-1270 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T5 | 1543-1548 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T6 | 1916-1921 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 120-128 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 189-213 | Disease | denotes | coronavirus disease 2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 215-223 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 334-369 | Disease | denotes | acute respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0006502 |
T5 | 340-369 | Disease | denotes | respiratory distress syndrome | http://purl.obolibrary.org/obo/MONDO_0009971 |
T6 | 371-375 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T7 | 436-444 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T8 | 662-670 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T9 | 1416-1420 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
T10 | 1667-1675 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T11 | 1776-1788 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T12 | 1816-1834 | Disease | denotes | multiorgan failure | http://purl.obolibrary.org/obo/MONDO_0043726 |
T13 | 2010-2022 | Disease | denotes | coagulopathy | http://purl.obolibrary.org/obo/MONDO_0001531 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 35-40 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | Blood |
T2 | 35-40 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | Blood |
T3 | 95-96 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T4 | 139-140 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 504-509 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T6 | 504-509 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T7 | 779-784 | http://purl.obolibrary.org/obo/CLO_0053704 | denotes | IL- 8 |
T8 | 979-984 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T9 | 979-984 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T10 | 1070-1080 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activation |
T11 | 1119-1122 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | Ten |
T12 | 1266-1270 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T13 | 1266-1270 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T14 | 1543-1554 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood cells |
T15 | 1596-1597 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T16 | 1916-1921 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T17 | 1916-1921 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 772-774 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T3 | 779-781 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T5 | 809-814 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
T6 | 827-834 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T7 | 1050-1057 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T8 | 1232-1238 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
T9 | 1573-1575 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
T11 | 1864-1871 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 793-801 | http://purl.obolibrary.org/obo/GO_0070265 | denotes | necrosis |
T2 | 793-801 | http://purl.obolibrary.org/obo/GO_0019835 | denotes | necrosis |
T3 | 793-801 | http://purl.obolibrary.org/obo/GO_0008219 | denotes | necrosis |
T4 | 793-801 | http://purl.obolibrary.org/obo/GO_0001906 | denotes | necrosis |
T5 | 1081-1089 | http://purl.obolibrary.org/obo/GO_0050817 | denotes | clotting |
T6 | 1776-1788 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2 | 120-128 | Disease | denotes | COVID-19 | MESH:C000657245 |
3 | 129-137 | Species | denotes | Patients | Tax:9606 |
35 | 189-213 | Disease | denotes | coronavirus disease 2019 | MESH:C000657245 |
36 | 215-223 | Disease | denotes | COVID-19 | MESH:C000657245 |
37 | 334-369 | Disease | denotes | acute respiratory distress syndrome | MESH:D012128 |
38 | 371-375 | Disease | denotes | ARDS | MESH:D012128 |
39 | 436-444 | Disease | denotes | COVID-19 | MESH:C000657245 |
40 | 445-453 | Species | denotes | patients | Tax:9606 |
41 | 546-560 | Chemical | denotes | heparinisation | |
42 | 603-611 | Species | denotes | patients | Tax:9606 |
43 | 662-670 | Disease | denotes | COVID-19 | MESH:C000657245 |
44 | 759-777 | Gene | denotes | interleukin (IL)-6 | Gene:3569 |
45 | 779-784 | Gene | denotes | IL- 8 | Gene:3576 |
46 | 786-801 | Disease | denotes | tumour necrosis | MESH:D009336 |
47 | 816-834 | Gene | denotes | C-reactive protein | Gene:1401 |
48 | 836-839 | Gene | denotes | CRP | Gene:1401 |
49 | 908-918 | Gene | denotes | fibrinogen | Gene:2244 |
50 | 1050-1057 | Chemical | denotes | heparin | MESH:D006493 |
51 | 1123-1131 | Species | denotes | patients | Tax:9606 |
52 | 1157-1173 | Disease | denotes | critical disease | MESH:D016638 |
53 | 1175-1183 | Disease | denotes | dyspnoea | MESH:D004417 |
54 | 1185-1192 | Disease | denotes | hypoxia | MESH:D000860 |
55 | 1232-1238 | Chemical | denotes | oxygen | MESH:D010100 |
56 | 1397-1405 | Species | denotes | patients | Tax:9606 |
57 | 1416-1420 | Disease | denotes | ARDS | MESH:D012128 |
58 | 1425-1429 | Disease | denotes | died | MESH:D003643 |
59 | 1573-1577 | Gene | denotes | IL-6 | Gene:3569 |
60 | 1610-1613 | Gene | denotes | CRP | Gene:1401 |
61 | 1618-1628 | Gene | denotes | fibrinogen | Gene:2244 |
62 | 1667-1675 | Disease | denotes | COVID-19 | MESH:C000657245 |
63 | 1776-1788 | Disease | denotes | inflammation | MESH:D007249 |
64 | 1864-1871 | Chemical | denotes | heparin | MESH:D006493 |
65 | 2010-2022 | Disease | denotes | coagulopathy | MESH:D001778 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-167 | Sentence | denotes | Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series. |
T2 | 168-181 | Sentence | denotes | INTRODUCTION: |
T3 | 182-377 | Sentence | denotes | Severe coronavirus disease 2019 (COVID-19) is characterised by hyperinflammatory state, systemic coagulopathies, and multiorgan involvement, especially acute respiratory distress syndrome (ARDS). |
T4 | 378-585 | Sentence | denotes | We here describe our preliminary clinical experience with COVID-19 patients treated via an early initiation of extracorporeal blood purification combined with systemic heparinisation and respiratory support. |
T5 | 586-594 | Sentence | denotes | METHODS: |
T6 | 595-695 | Sentence | denotes | Fifteen patients were included; several biomarkers associated with COVID-19 severity were monitored. |
T7 | 696-919 | Sentence | denotes | Personalised treatment was tailored according to the levels of interleukin (IL)-6, IL- 8, tumour necrosis factor alpha, C-reactive protein (CRP), neutrophilto- lymphocyte ratio, thrombocyte counts, D-dimers, and fibrinogen. |
T8 | 920-1109 | Sentence | denotes | Treatment consisted of respiratory support, extracorporeal blood purification using the AN69ST (oXiris®) hemofilter, and 300 U/kg heparin to maintain activation clotting time ≥ 180 seconds. |
T9 | 1110-1118 | Sentence | denotes | RESULTS: |
T10 | 1119-1301 | Sentence | denotes | Ten patients presented with severe to critical disease (dyspnoea, hypoxia, respiratory rate > 30/min, peripheral oxygen saturation < 90%, or > 50% lung involvement on X-ray imaging). |
T11 | 1302-1450 | Sentence | denotes | The median intensive care unit length of stay was 9.3 days (interquartile range 5.3-10.1); two patients developed ARDS and died after 5 and 26 days. |
T12 | 1451-1629 | Sentence | denotes | Clinical improvement was associated with normalisation (increase) of thrombocytes and white blood cells, stable levels of IL-6 (< 50 ng/mL), and a decrease of CRP and fibrinogen. |
T13 | 1630-1641 | Sentence | denotes | CONCLUSION: |
T14 | 1642-1835 | Sentence | denotes | Continuous monitoring of COVID-19 severity biomarkers and radiological imaging is crucial to assess disease progression, uncontrolled inflammation, and to avert irreversible multiorgan failure. |
T15 | 1836-2054 | Sentence | denotes | The combination of systemic heparin anticoagulation regimens and extracorporeal blood purification using cytokine-adsorbing hemofilters may reduce hyperinflammation, prevent coagulopathy, and support clinical recovery. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 279-293 | Phenotype | denotes | coagulopathies | http://purl.obolibrary.org/obo/HP_0003256 |
T2 | 340-360 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
T3 | 786-792 | Phenotype | denotes | tumour | http://purl.obolibrary.org/obo/HP_0002664 |
T4 | 1175-1183 | Phenotype | denotes | dyspnoea | http://purl.obolibrary.org/obo/HP_0002094 |
T5 | 1185-1192 | Phenotype | denotes | hypoxia | http://purl.obolibrary.org/obo/HP_0012418 |
T6 | 2010-2022 | Phenotype | denotes | coagulopathy | http://purl.obolibrary.org/obo/HP_0003256 |